CA2714757A1 - Low viscosity liquid polymeric delivery system - Google Patents

Low viscosity liquid polymeric delivery system Download PDF

Info

Publication number
CA2714757A1
CA2714757A1 CA2714757A CA2714757A CA2714757A1 CA 2714757 A1 CA2714757 A1 CA 2714757A1 CA 2714757 A CA2714757 A CA 2714757A CA 2714757 A CA2714757 A CA 2714757A CA 2714757 A1 CA2714757 A1 CA 2714757A1
Authority
CA
Canada
Prior art keywords
composition
liquid polymer
active agent
organic solvent
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2714757A
Other languages
French (fr)
Other versions
CA2714757C (en
Inventor
Richard L. Dunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dunn Research & Consulting LLC
Original Assignee
Dunn Research & Consulting LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dunn Research & Consulting LLC filed Critical Dunn Research & Consulting LLC
Priority to CA2787097A priority Critical patent/CA2787097C/en
Publication of CA2714757A1 publication Critical patent/CA2714757A1/en
Application granted granted Critical
Publication of CA2714757C publication Critical patent/CA2714757C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/04—Macromolecular materials
    • A61L29/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A61L29/085—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/43—Hormones, e.g. dexamethasone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A61L2300/604—Biodegradation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions

Abstract

Low viscosity biodegradable polymer solutions of a liquid biodegradable polymer and biocompatible solvent and methods using the compositions to form a biodegradable liquid polymer implant are provided. Liquid biodegradable polymers are dissolved in non-toxic biocompatible organic solvents to form low viscosity solutions that can be easily injected into the body with standard syringes and small gauge needles. Once the liquid polymer solution is placed within the body, the solvent dissipates or diffuses away from the polymer leaving a more viscous liquid polymer implant suitable, for example, for delivery of a biologically active agent or for use as a medical or surgical device. Because the polymer composition is a low viscosity liquid, it can be injected into muscle or subcutaneous tissue without damage to the surrounding tissue and without the noticeable bump observed with solid implant.

Claims (30)

1. A liquid polymer composition, comprising:
(a) a biodegradable liquid polymer comprising a copolymer of lactide and caprolactone with a molar ratio from 75/25 to 25/75 and a molecular weight of 2000 daltons to 20,000 daltons, the molecular weight as determined by gel permeation chromatography using a multi-angle light-scattering detector (GPC-MALS);
(b) a biocompatible organic solvent; and (c) a therapeutically effective amount of a biologically active agent;
wherein the composition, when placed in contact with an aqueous medium or body fluid remains in a liquid form and does not form a solid in situ.
2. The composition of Claim 1, wherein the solvent comprises a hydrophilic organic solvent having a water solubility greater than 10% by weight of said solvent in water.
3. The composition of Claim 1, wherein the solvent comprises a hydrophilic organic solvent selected from the group consisting of N-methyl-2-pyrrolidone, 2-pyrrolidone, N-ethyl-2-pyrrolidone, N-cyclohexyl-2-pyrrolidone, N-hydroxethyl-2-pyrrolidone, dimethyl acetamide, dimethyl formamide, acetic acid, lactic acid, ethanol, propanol, methyl lactate, ethyl lactate, methyl acetate, dlethylene glycol monomethyl ether, glycofurol, glycerol formal, isopropylidene glycerol, dimethyl sulfoxide, c-caprolactone, butyrolactone, propylene glycol, polyethylene glycol, glycerol, 1,3-butyleneglycol, methoxypolyethylene glycol, methoxypropylene glycol, acetone, methyl ethyl ketone, tetrahydrofuran, and combinations thereof.
4. The composition of Claim 1, wherein the solvent comprises a hydrophilic organic solvent selected from the group consisting of N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethyl acetamide, dimethyl sulfoxide, ethyl lactate, glycofurol, glycerol formal, isopropylidene glycerol, propylene glycol, polyethylene glycol, methoxypolyethylene glycol, methoxypropylene glycol, and combinations thereof.

Claims
5. The composition of Claim 1, wherein the solvent comprises a lipophilic organic solvent having a water solubility less than 10% by welght of the solvent in water.
6. The composition of Claim 1, wherein the solvent comprises a lipophilic organic solvent selected from the group consisting of ethyl acetate, ethyl butyrate, ethyl oleate, isopropyl palmitate, ethyl paimitate, methyl paimitate, isopropyl myristate, diethyl malonate, diethyl succinate, dimethyl adipate, dimethyl succinate, dibutyl sebacate, triacetin, triethyl citrate, tributyrin, acetyl triethyl citrate, acetyl tributyl citrate, acetyl trihexyl citrate, butyryl trihexyl citrate, tributyl citrate, caprylic/capric triglycerides, caprylic%apric/linoleic triglyceride, caprylic/capric/succinic triglyceride, propylene glycol dicaprylate/caprate, benzyl alcohol, ethyl benzoate, benzyl benzoate, propylene carbonate, dimethyl carbonate, N,N-diethyl-toluamide, N-dodecyl-2-pyrrolidone, N-octyl-2-pyrrolidone, N-methyl-2-caprolactam, N-dodecyl-caprolactam, heptanoic acid, oleic acid, sesame oil, peanut oil, castor oil, and combinations thereof.
7. The composition of Claim 1, wherein the solvent comprises a lipophilic organic solvent selected from the group consisting of ethyl acetate, ethyl oleate, isopropyl myristate, triacetin, triethyl citrate, acetyl tributyl citrate, ethyl benzoate, benzyl benzoate, sesame oil, and combinations thereof.
8. The composition of Claim 1, wherein the solvent comprises a combination of a hydrophilic solvent and a lipophilic solvent.
9. The composition of Claim 1, wherein the biodegradable liquid polymer is pharmaceutically-acceptable.
10. The composition of Claim 1, wherein the organic solvent is dissolvable or dispersible in situ in a body fluid.

Claims
11. The composition of Claim 1, wherein the composition when placed in a body forms a biodegradable polymeric implant having a liquid consistency.
12. The composition of Claim 1, comprising 30-90% by weight liquid polymer and 10-70% by weight organic solvent, the % by weight based on the total weight of the composition.
13. The composition of Claim 1, comprising 0.1-30% by weight active agent.
14. The composition of Claim 1, wherein the biologically active agent is selected from the group consisting of cisplatin, carbopiatin, anastozoie, fulvestrant, exemestane, estradiol, testosterone, misoprostol, follicle-stimulating hormone, dustasteride, doxycyciine, ciprofloxacin, quinolone, ivermectin, haloperidol, diazepam, risperidone, olanzapine, naltrexone, fentanyl, buprenorphine, butorphanol, loperamide, nafarelin, buserelin, histrelin, deslorelin, Ieuprolide, goserelin, triptorelin, ganirelix, abarelix, cetrorelix, teverelix, octreotide, Ianreotide, human growth hormone, interferon-alpha, interferon-beta, interferon-gamma, interleukin, calcitonin, growth hormone releasing peptides, glucagon-like peptides, granulocyte-colony stimulating factor, nerve growth factor, platelet-de rived growth factor, insulin-like growth factor, vascular endothelial growth factor, fibroblast growth factor, bone morphogenic protein, erythropoletin, and salts, complexes, prodrugs, and analogs thereof.
15. The composition of Claim 1, wherein the organic solvent comprises N-methyl-2-pyrrolidone, and the biologically active agent is selected from the group consisting of cisplatin, carboplatin, buprenorphine, doxycyline, haloperidol, and triptorelin pamoate.
16. The composition of Claim 1, wherein the organic solvent comprises triacetin, and the biologically active agent comprises triptorelin pamoate.

Claims
17. The composition of Claim 1, wherein the copolymer of lactide and caprolactone has a molecular weight of 3,000 daltons to 12,000 daltons.
18. The composition of any of Claims 1-17, wherein the biodegradable liquid polymer is a liquid at 25°C up to 37°C.
19. The composition of any of Claims 1-18, packaged for use in forming a biodegradable polymeric material or implant within a body.
20. The composition of any of Claims 1-18, for use as a biodegradable polymeric implant to deliver the biologically active agent into a body.
21. Use of the composition of any of Claims 1-18, in the preparation of a medicament for forming a biodegradable polymeric material or implant within a body to deliver the biologically active agent into the body.
22. A method of forming a biodegradable polymeric implant within a body, comprising:
administering into the body an amount of a liquid polymer composition comprising:
(a) a pharmaceutically acceptable, biodegradable liquid polymer comprising a copolymer of lactide and caprolactone with a molar ratio from 75/25 to 25/75 and a molecular weight of 2000 daltons to 20,000 daltons, the molecular weight as determined by gel permeation chromatography using a multi-angle liqht-scattering detector (GPC-MALS);

(b) a biocompatible organic solvent that is dissolvable or dispersible in situ in a body fluid; and (c) a therapeutically effective amount of a biologically active agent; and Claims allowing the solvent to dissipate into body fluids to form the biodegradable polymeric material having a liquid consistency which does not form into a solid in situ;
wherein the polymeric material releases the biologically active agent as the polymeric material biodegrades within the body.
23. The method of Claim 22, wherein the liquid polymer composition is administered through a syringe or needle of 18-26 gauge.
24. The method of Claim 22, wherein the liquid polymer composition is administered into a body tissue of the subject to form a liquid implant.
25. The method of Claim 22, wherein the implant is in the form of a film.
26. The method of Claim 22, wherein the implant is in the form of a plug situated within the body tissue.
27. The method of Claim 22, wherein the liquid polymer composition is administered onto a device selected from the group consisting of a catheter, a mesh, a screw, a plate, a tack, a pin, a staple, and a sponge, and the method further comprises placing the device with the composition thereon into the body of the subject.
28. The method of any of Claims 22-27, further comprising, prior to administering the liquid polymer composition into the body, dissolving the biodegradable liquid polymer in the organic solvent, and adding an effective amount of the biologically active agent to the composition.
29. A kit comprising in association, at least one of:
a) a container of a pharmaceutically acceptable, biodegradable liquid polymer comprising a copolymer of lactide and caprolactone with a molar ratio from 75/25 to 25175 and a molecular weight of 2000 daltons to Claims 20,000 daltons, the molecular weight as determined by gel permeation chromatography using a multi-angle light-scattering detector (GPC-MALS);

a container of a biocompatible organic solvent that is dissolvable or dispersible in situ in a body fluid; and a container of a therapeutically effective amount of a biologically active agent;

wherein the liquid polymer, the organic solvent and the biologically active agent when combined, will form a liquid polymer composition;

or b) a container of a liquid composition comprising:
(i) a pharmaceutically acceptable, biodegradable liquid polymer comprising a copolymer of lactide and caprolactone with a molar ratio from 75/25 to 25/75 and a molecular weight of 2000 daltons to 20,000 daltons, the molecular weight as determined by gel permeation chromatography using a mufti-angle light-scattering detector (GPC-MALS), dissolved in (ii) a biocompatible organic solvent that is dissolvable or dispersible in situ in a body fluid; and a container of a therapeutically effective amount of a biologically active agent;
wherein the liquid composition of the polymer and organic solvent when combined with the biologically active agent will form a liquid polymer composition;

or c) a container of a liquid polymer composition comprising (i) a pharmaceutically acceptable, biodegradable liquid polymer comprising a copolymer of lactide and caprolactone with a molar Claims ratio from 75/25 to 25175 and a molecular weight of 2000 daltons to 20,000 daltons, the molecular weight as determined by gel permeation chromatography using a multi-angle light-scattering detector (GPC-MALS), dissolved in (ii) a biocompatible organic solvent that is dissolvable or dispersible in situ in a body fluid; and (iii) a therapeutically effective amount of a biologically active agent;
wherein the liquid polymer composition of a) or b) or c), when placed in contact with body fluid, will form a biodegradable polymeric implant having a liquid consistency which does not form into a solid in situ and the biologically active agent will be released into the body as the polymeric implant blodegrades within the body;
in combination with:
d) directions for preparation and/or administration of the liquid polymer composition to form the polymeric implant.
30. The kit of Claim 29, wherein the container of the biologically active agent of a) or b) comprises a pharmaceutically acceptable carrier or diluent.
CA2714757A 2008-01-14 2009-01-13 Low viscosity liquid polymeric delivery system Active CA2714757C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2787097A CA2787097C (en) 2008-01-14 2009-01-13 Low viscosity liquid polymeric delivery system

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1391208A 2008-01-14 2008-01-14
US12/013,912 2008-01-14
US12/100,562 US20090181068A1 (en) 2008-01-14 2008-04-10 Low Viscosity Liquid Polymeric Delivery System
US12/100,562 2008-04-10
PCT/US2009/030853 WO2009091737A2 (en) 2008-01-14 2009-01-13 Low viscosity liquid polymeric delivery system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2787097A Division CA2787097C (en) 2008-01-14 2009-01-13 Low viscosity liquid polymeric delivery system

Publications (2)

Publication Number Publication Date
CA2714757A1 true CA2714757A1 (en) 2009-07-23
CA2714757C CA2714757C (en) 2012-10-16

Family

ID=40459715

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2714757A Active CA2714757C (en) 2008-01-14 2009-01-13 Low viscosity liquid polymeric delivery system
CA2787097A Active CA2787097C (en) 2008-01-14 2009-01-13 Low viscosity liquid polymeric delivery system

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2787097A Active CA2787097C (en) 2008-01-14 2009-01-13 Low viscosity liquid polymeric delivery system

Country Status (10)

Country Link
US (3) US20090181068A1 (en)
EP (2) EP2244752B1 (en)
AT (1) ATE526046T1 (en)
CA (2) CA2714757C (en)
CY (1) CY1113604T1 (en)
HK (1) HK1150982A1 (en)
PL (1) PL2244752T3 (en)
PT (1) PT2244752E (en)
SI (1) SI2244752T1 (en)
WO (1) WO2009091737A2 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225033A1 (en) * 2010-11-24 2012-09-06 Durect Corporation Biodegradable Drug Delivery Composition
KR101443926B1 (en) 2006-06-15 2014-10-02 마이크로벤션, 인코포레이티드 Embolization device constructed from expansible polymer
EP2266639B1 (en) 2007-12-21 2016-10-05 MicroVention, Inc. Methods for preparing hydrogel filaments for biomedical use
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
WO2009111057A2 (en) 2008-03-07 2009-09-11 Scidose Llc Fulvestrant formulations
WO2011022861A1 (en) 2009-08-31 2011-03-03 西安力邦医药科技有限责任公司 Fulvestrant nanosphere/microsphere and preparative method and use thereof
JP5722333B2 (en) 2009-10-26 2015-05-20 マイクロベンション インコーポレイテッド Embolization device composed of expandable polymer
ES2677012T3 (en) 2010-01-13 2018-07-27 Ipsen Pharma S.A.S. Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogues
ES2390439B1 (en) * 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. INJECTABLE COMPOSITION
US8975270B2 (en) * 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
GB2513267B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
US9168251B2 (en) 2010-09-03 2015-10-27 Zoetis Belgium S.A High dose buprenorphine compositions and use as analgesic
WO2012145431A2 (en) 2011-04-18 2012-10-26 Microvention, Inc. Embolic devices
FR2975912B1 (en) * 2011-05-30 2013-06-14 Flamel Tech Sa CONTROLLED RELEASE COMPOSITION OF BUPRENORPHINE
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013078422A2 (en) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN102600073B (en) * 2012-03-31 2014-01-01 莱普德制药有限公司 Lactate-based fulvestrant or fulvestrant derivative oily preparation and preparation method of oily preparation
US11179468B2 (en) * 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
US9011884B2 (en) 2012-04-18 2015-04-21 Microvention, Inc. Embolic devices
CA2876474C (en) 2012-06-14 2021-06-22 Microvention, Inc. Polymeric treatment compositions
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9937164B2 (en) * 2012-07-26 2018-04-10 Camurus Ab Opioid formulations
SG11201500554XA (en) * 2012-07-26 2015-02-27 Camurus Ab Opioid formulations
CN104717983B (en) 2012-10-15 2018-09-18 微仙美国有限公司 It polymerize therapeutic combination
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR102370470B1 (en) 2013-03-15 2022-03-04 헤론 테라퓨틱스 인코포레이티드 Compositions of a polyorthoester and an aprotic solvent
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
EP3003272A1 (en) 2013-06-03 2016-04-13 Tolmar, Inc. Corticosteroid compositions
US10111956B2 (en) 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US10124090B2 (en) 2014-04-03 2018-11-13 Terumo Corporation Embolic devices
WO2015167752A1 (en) 2014-04-29 2015-11-05 Microvention, Inc. Polymers including active agents
WO2015167751A1 (en) 2014-04-29 2015-11-05 Microvention, Inc. Polymers
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AU2015341490C1 (en) 2014-11-07 2021-03-11 Indivior Uk Limited Buprenorphine dosing regimens
WO2016201250A1 (en) 2015-06-11 2016-12-15 Microvention, Inc. Expansile device for implantation
CA2988992A1 (en) * 2015-06-19 2016-12-22 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
WO2017024027A1 (en) * 2015-08-03 2017-02-09 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
CA2998504C (en) 2015-09-21 2023-06-20 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
US10368874B2 (en) 2016-08-26 2019-08-06 Microvention, Inc. Embolic compositions
US10744132B2 (en) * 2016-09-13 2020-08-18 Alar Pharmaceuticals, Inc. Sustained-release buprenorphine formulations
AU2018217064A1 (en) * 2017-01-31 2019-08-08 Veru Inc. Compositions and methods for long term release of Gonadotropin-releasing hormone (GnRH) antagonists
AU2018238136A1 (en) 2017-03-20 2019-11-07 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
EP3694422A4 (en) 2017-10-09 2021-06-30 Microvention, Inc. Radioactive liquid embolic
TW202027725A (en) 2018-09-25 2020-08-01 愛爾蘭商托爾瑪國際有限公司 Liquid polymer delivery system for extended administration of drugs
KR20220075338A (en) 2019-09-30 2022-06-08 톨마 인터내셔날 리미티드 Liquid Polymer Compositions and Systems for Prolonged Delivery of Peptides as Active Pharmaceutical Ingredients
US11547226B2 (en) 2020-06-24 2023-01-10 Clean Lidz Llc Food protection apparatuses, assemblies, and methods of use
WO2022069996A1 (en) 2020-09-30 2022-04-07 Tolmar International Limited Biodegradable polymer and solvent compositions and systems for extended storage and delivery of active pharmaceutical ingredients
CN112190567B (en) * 2020-11-09 2022-03-11 山东华辰制药有限公司 Preparation method and application of ivermectin sustained-release microspheres
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form
CA3227324A1 (en) 2021-07-06 2023-01-12 Mark Hasleton Treatment of serotonin reuptake inhibitor withdrawal syndrome
CN114602333B (en) * 2022-04-08 2023-08-25 上海翊科聚合物科技有限公司 Preparation method of poly 4-methyl-1-pentene hollow fiber membrane
WO2024003291A1 (en) 2022-06-30 2024-01-04 Virbac Deslorelin use in chemical castration of a non-human mammal related to pk/pd interaction

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE758156R (en) 1970-05-13 1971-04-28 Ethicon Inc ABSORBABLE SUTURE ELEMENT AND ITS
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4186189A (en) 1977-09-28 1980-01-29 Ethicon, Inc. Absorbable pharmaceutical compositions based on poly(alkylene oxalates)
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4379138A (en) 1981-12-28 1983-04-05 Research Triangle Institute Biodegradable polymers of lactones
US4582052A (en) * 1982-03-23 1986-04-15 Repromed, Inc. Povidone-iodine dispensing fiber
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4523591A (en) * 1982-10-22 1985-06-18 Kaplan Donald S Polymers for injection molding of absorbable surgical devices
US4906474A (en) * 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4655777A (en) * 1983-12-19 1987-04-07 Southern Research Institute Method of producing biodegradable prosthesis and products therefrom
US4650488A (en) * 1984-05-16 1987-03-17 Richards Medical Company Biodegradable prosthetic device
US4891225A (en) * 1984-05-21 1990-01-02 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4841968A (en) * 1986-09-26 1989-06-27 Southern Research Institute Antithrombotic/thrombolytic suture and methods of making and using the same
DE3717060A1 (en) * 1987-05-21 1988-12-01 Bayer Ag POLYETHER-POLYCARBONATE-DIOLE, THEIR PRODUCTION AND USE AS STARTING PRODUCTS FOR POLYURETHANE PLASTICS
US4804691A (en) * 1987-08-28 1989-02-14 Richards Medical Company Method for making a biodegradable adhesive for soft living tissue
US5160737A (en) * 1988-05-03 1992-11-03 Perio Products Ltd. Liquid polymer composition, and method of use
US5068220A (en) * 1988-07-26 1991-11-26 Sharpoint L.P. Biodegradable polyamides for providing a controlled release therapeutic drug
US4950735A (en) * 1988-07-26 1990-08-21 Sharpoint L.P. Biodegradable polyamides
US5725491A (en) * 1988-10-03 1998-03-10 Atrix Laboratories, Inc. Method of forming a biodegradable film dressing on tissue
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5632727A (en) * 1988-10-03 1997-05-27 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324520A (en) * 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US4975271A (en) * 1988-12-19 1990-12-04 Vipont Pharmaceutical, Inc. Muscosal delivery systems for treatment of periodontal disease
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
USRE37950E1 (en) * 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
US5620700A (en) * 1990-10-30 1997-04-15 Alza Corporation Injectable drug delivery system and method
WO1992007555A1 (en) * 1990-10-30 1992-05-14 Alza Corporation Drug delivery system and method
CA2060223C (en) * 1991-02-12 1999-07-20 Clarence C. Lee Injectable medical lubricating fluid composition and method of use
DE4112489C2 (en) * 1991-04-17 1994-06-09 Christian Dr Med Juergens Use of resorbable, physiologically harmless copolymers for the topical treatment of human or animal skin
AU2605592A (en) * 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
EP0560014A1 (en) * 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US5576418A (en) * 1992-06-29 1996-11-19 Jurgens; Christian Resorbable biocompatible copolymers and their use
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
JP3220331B2 (en) * 1993-07-20 2001-10-22 エチコン・インコーポレーテツド Absorbable liquid copolymers for parenteral administration
JP3257750B2 (en) * 1993-07-20 2002-02-18 エチコン・インコーポレーテツド Liquid copolymer of ε-caprolactone and lactide
US5442033A (en) * 1993-07-20 1995-08-15 Ethicon, Inc. Liquid copolymers of epsilon-caprolactone and lactide
JPH09511666A (en) * 1994-04-08 1997-11-25 アトリックス・ラボラトリーズ・インコーポレイテッド Ancillary polymer systems for use in medical devices
PT754032E (en) * 1994-04-08 2002-05-31 Atrix Lab Inc LIQUID COMPOSITIONS FOR DIFFUSE
US5599852A (en) * 1994-10-18 1997-02-04 Ethicon, Inc. Injectable microdispersions for soft tissue repair and augmentation
AU706434B2 (en) * 1994-10-18 1999-06-17 Ethicon Inc. Injectable liquid copolymers for soft tissue repair and augmentation
US6335383B1 (en) * 1994-10-18 2002-01-01 Ethicon, Inc. Microdispersions for coating surgical devices
WO1996021427A1 (en) * 1995-01-09 1996-07-18 Atrix Laboratories, Inc. Liquid polymer delivery system
US5962023A (en) * 1995-03-06 1999-10-05 Ethicon, Inc. Hydrogels containing absorbable polyoxaamides
US5464929A (en) * 1995-03-06 1995-11-07 Ethicon, Inc. Absorbable polyoxaesters
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5722950A (en) * 1995-06-07 1998-03-03 Atrix Laboratories, Inc. Method for remote delivery of an aerosolized liquid
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6096344A (en) * 1995-07-28 2000-08-01 Advanced Polymer Systems, Inc. Bioerodible porous compositions
US5747637A (en) * 1995-09-07 1998-05-05 Mitsui Toatsu Chemicals, Inc. Bioabsorbable polymer and process for preparing the same
US5736152A (en) * 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
DK0959873T3 (en) * 1996-12-20 2006-07-03 Alza Corp Gel composition and methods
US6051558A (en) * 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US5962006A (en) * 1997-06-17 1999-10-05 Atrix Laboratories, Inc. Polymer formulation for prevention of surgical adhesions
ES2359973T3 (en) 1998-03-19 2011-05-30 MERCK SHARP & DOHME CORP. LIQUID POLYMER COMPOSITIONS FOR THE CONTROLLED RELEASE OF BIOACTIVE SUBSTANCES.
KR100684055B1 (en) * 1998-03-19 2007-02-16 머크 앤드 캄파니 인코포레이티드 Liquid polymeric compositions for controlled release of bioactive substances
US7128927B1 (en) 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US6177094B1 (en) * 1998-04-30 2001-01-23 United States Surgical Corporation Bioabsorbable blends and coating composition containing same
US6245345B1 (en) * 1998-07-07 2001-06-12 Atrix Laboratories, Inc. Filamentous porous films and methods for producing the same
US6261583B1 (en) * 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6818018B1 (en) 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US8197461B1 (en) 1998-12-04 2012-06-12 Durect Corporation Controlled release system for delivering therapeutic agents into the inner ear
US6835194B2 (en) 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6482872B2 (en) * 1999-04-01 2002-11-19 Programmable Materials, Inc. Process for manufacturing a biodegradable polymeric composition
US6291013B1 (en) * 1999-05-03 2001-09-18 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
US6352667B1 (en) * 1999-08-24 2002-03-05 Absorbable Polymer Technologies, Inc. Method of making biodegradable polymeric implants
US7025980B1 (en) * 1999-09-14 2006-04-11 Tepha, Inc. Polyhydroxyalkanoate compositions for soft tissue repair, augmentation, and viscosupplementation
US8226598B2 (en) * 1999-09-24 2012-07-24 Tolmar Therapeutics, Inc. Coupling syringe system and methods for obtaining a mixed composition
US6461631B1 (en) * 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
KR100416242B1 (en) 1999-12-22 2004-01-31 주식회사 삼양사 Liquid composition of biodegradable block copolymer for drug delivery and process for the preparation thereof
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
AU5911101A (en) 2000-04-19 2001-10-30 Genentech Inc Sustained release formulations
US6613355B2 (en) * 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US6726920B1 (en) 2000-09-22 2004-04-27 Durect Corporation Implantable drug delivery patch
US6730772B2 (en) 2001-06-22 2004-05-04 Venkatram P. Shastri Degradable polymers from derivatized ring-opened epoxides
US6967234B2 (en) 2002-12-18 2005-11-22 Ethicon, Inc. Alkyd-lactone copolymers for medical applications
KR20040058100A (en) * 2001-11-14 2004-07-03 알자 코포레이션 Injectable depot compositions and uses thereof
DE60239556D1 (en) * 2001-11-14 2011-05-05 Durect Corp CATHETERINJICIBLE DEPOT COMPOSITIONS AND THEIR USE
BR0206469A (en) * 2001-11-14 2004-01-13 Alza Corp Injectable Depot Composition
KR100629380B1 (en) * 2001-11-30 2006-09-29 화이자 인코포레이티드 Controlled release polymeric compositions of bone growth promoting compounds
EP1334990A1 (en) * 2002-02-06 2003-08-13 Polyganics B.V. DL-Lactide-epsilon-caprolactone copolymers
US7005136B2 (en) 2002-03-29 2006-02-28 Ethicon, Inc. Bone replacement materials utilizing bioabsorbable liquid polymers
US7326426B2 (en) * 2002-03-29 2008-02-05 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable liquid polymers
DE60325742D1 (en) * 2002-07-31 2009-02-26 Alza Corp INJECTABLE MULTIMODAL POLYMERS DEPOT COMPOSITIONS AND THEIR USES
CA2494342A1 (en) * 2002-07-31 2004-02-12 Alza Corporation Injectable depot compositions and uses thereof
US6872799B2 (en) 2002-12-18 2005-03-29 Ethicon, Inc. Functionalized polymers for medical applications
WO2004081196A2 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
US20070184084A1 (en) * 2003-05-30 2007-08-09 Guohua Chen Implantable elastomeric caprolactone depot compositions and uses thereof
JP4627315B2 (en) * 2004-03-23 2011-02-09 エフ．ホフマン−ラ ロシュ アーゲー Benzylpyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors
BRPI0513858B8 (en) * 2004-07-27 2021-05-25 Hoffmann La Roche benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors, their preparation process, their use and pharmaceutical composition comprising them
CA2582374A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
JP5244394B2 (en) * 2004-11-10 2013-07-24 トルマー セラピューティクス， インコーポレイテッド． Stabilized polymer delivery system
US20070161097A1 (en) * 2005-02-28 2007-07-12 The Procter & Gamble Company Deregulated bacteria with improved polyhydroxyalkanoate production
CA2705520C (en) 2007-11-13 2016-06-28 Surmodics Pharmaceuticals, Inc. Viscous terpolymers as drug delivery platform
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System

Also Published As

Publication number Publication date
CA2787097A1 (en) 2009-07-23
US20090181068A1 (en) 2009-07-16
EP2244752B1 (en) 2011-09-28
EP2371400A2 (en) 2011-10-05
PT2244752E (en) 2011-12-06
CA2787097C (en) 2014-09-16
CA2714757C (en) 2012-10-16
US20120183629A1 (en) 2012-07-19
SI2244752T1 (en) 2012-01-31
CY1113604T1 (en) 2016-06-22
HK1150982A1 (en) 2012-01-20
PL2244752T3 (en) 2012-02-29
ATE526046T1 (en) 2011-10-15
WO2009091737A2 (en) 2009-07-23
WO2009091737A3 (en) 2010-05-27
US8187640B2 (en) 2012-05-29
EP2371400A3 (en) 2012-03-28
US20110027389A1 (en) 2011-02-03
EP2244752A2 (en) 2010-11-03

Similar Documents

Publication Publication Date Title
CA2714757A1 (en) Low viscosity liquid polymeric delivery system
EP3360538B1 (en) Injectable flowable composition comprising buprenorphine
CA2687979C (en) Sustained delivery formulations of risperidone compounds
US10592168B1 (en) Injectable flowable composition comprising buprenorphine
US8975270B2 (en) Injectable flowable composition comprising buprenorphine
JP2008524235A5 (en)
JP2016510041A (en) Injectable local anesthetic semi-solid preparation and composition thereof
NZ554904A (en) In-situ forming implant for animals
US20230346877A1 (en) Pharmaceutical Compositions having a Selected Release Duration
ES2370377T3 (en) SYSTEM OF ADMINISTRATION OF A LOW VISCOSITY POLYMER LIQUID.
US20090292013A1 (en) In-Situ Forming Implant for Animals

Legal Events

Date Code Title Description
EEER Examination request